Sulfonylurea challenge test in subjects diagnosed with type 1 diabetes mellitus

Pediatric Diabetes

Volumn 18, Issue 8, 2017, Pages 777-784

  Remedi, Maria S ^a   Thomas, Mareen ^a,b   Nichols, Colin G ^a   Marshall, Bess A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

diabetes mellitus; neonatal diabetes; sulfonylurea; treatment; type 1 diabetes

Indexed keywords

ANTIBODY; C PEPTIDE; GLIPIZIDE; GLUCOSE; GLUTAMATE DECARBOXYLASE; HEMOGLOBIN A1C; INSULIN; PANCREAS ISLET CELL ANTIBODY; SULFONYLUREA; SULFONYLUREA DERIVATIVE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; BLOOD ANALYSIS; CHILD; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG HALF LIFE; DRUG RESPONSE; FEMALE; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; KETONURIA; MALE; MIDDLE AGED; NEWBORN DIABETES MELLITUS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROVOCATION TEST; SCHOOL CHILD; SINGLE DRUG DOSE; YOUNG ADULT; CASE CONTROL STUDY; SECRETION (PROCESS);

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INSULIN; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS; YOUNG ADULT;

EID: 85033660747     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12489     Document Type: Article

References (25)

1. Hameed S, Ellard S, Woodhead HJ, et al. Persistently autoantibody negative (PAN) type 1 diabetes mellitus in children. Pediatr Diabetes. 2011;12(3, pt 1):142-149.
2. Dabelea D, Pihoker C, Talton JW, et al. Etiological approach to characterization of diabetes type: the SEARCH for Diabetes in Youth Study. Diabetes Care. 2011;34(7):1628-1633.
3. Rubio-Cabezas O, Hattersley AT, Njolstad PR, et al. ISPAD Clinical Practice Consensus Guidelines 2014. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes. 2014;15(suppl 20):47-64.
4. Remedi MS, Kurata HT, Scott A, et al. Secondary consequences of beta cell inexcitability: identification and prevention in a murine model of K(ATP)-induced neonatal diabetes mellitus. Cell Metab. 2009;9(2):140-151.
5. Denton JS, Jacobson DA. Channeling dysglycemia: ion-channel variations perturbing glucose homeostasis. Trends Endocrinol Metab. 2012;23(1):41-48.
6. Remedi MS, Nichols CG. Hyperinsulinism and diabetes: genetic dissection of beta cell metabolism-excitation coupling in mice. Cell Metab. 2009;10(6):442-453.
7. Gloyn AL, Cummings EA, Edghill EL, et al. Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 gene encoding the Kir6.2 subunit of the beta-cell potassium adenosine triphosphate channel. J Clin Endocrinol Metab. 2004;89(8):3932-3935.
8. Koster JC, Permutt MA, Nichols CG. Diabetes and insulin secretion: the ATP-sensitive K+ channel (K ATP) connection. Diabetes. 2005;54(11):3065-3072.
9. Flanagan SE, Clauin S, Bellanne-Chantelot C, et al. Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat. 2009;30(2):170-180.
10. Gloyn AL, Weedon MN, Owen KR, et al. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes. 2003;52(2):568-572.
11. Pearson ER, Flechtner I, Njolstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 2006;355(5):467-477.
12. Wambach JA, Marshall BA, Koster JC, White NH, Nichols CG. Successful sulfonylurea treatment of an insulin-naive neonate with diabetes mellitus due to a KCNJ11 mutation. Pediatr Diabetes. 2010;11(4):286-288.
13. Marshall BA, Green RP, Wambach J, White NH, Remedi MS, Nichols CG. Remission of severe neonatal diabetes with very early sulfonylurea treatment. Diabetes Care. 2015;38(3):e38-e39.
14. Babiker T, Vedovato N, Patel K, et al. Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes. Diabetologia. 2016;59(6):1162-1166.
15. Sagen JV, Pearson ER, Johansen A, et al. Preserved insulin response to tolbutamide in hepatocyte nuclear factor-1alpha mutation carriers. Diabet Med. 2005;22(4):406-409.
16. Remedi MS, Agapova SE, Vyas AK, Hruz PW, Nichols CG. Acute sulfonylurea therapy at disease onset can cause permanent remission of KATP-induced diabetes. Diabetes. 2011;60(10):2515-2522.
17. Girard CA, Wunderlich FT, Shimomura K, et al. Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest. 2009;119(1):80-90.
18. Remedi MS, Koster JC. K(ATP) channelopathies in the pancreas. Pflugers Arch. 2010;460(2):307-320.
19. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013;36(suppl 1):S67-S74.
20. Temple IK, Shield JP. 6q24 transient neonatal diabetes. Rev Endocr Metab Disord. 2010;11(3):199-204.
21. Greeley SA, Tucker SE, Worrell HI, Skowron KB, Bell GI, Philipson LH. Update in neonatal diabetes. Curr Opin Endocrinol Diabetes Obes. 2010;17(1):13-19.
22. Davis SN, Piatti PM, Monti L, et al. Proinsulin and insulin concentrations following intravenous glucose challenges in normal, obese, and non-insulin-dependent diabetic subjects. Metabolism. 1993; 42(1):30-35.
23. Oram RA, Jones AG, Besser RE, et al. The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia. 2014;57(1):187-191.
24. Keenan HA, Sun JK, Levine J, et al. Residual insulin production and pancreatic ss-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes. 2010;59(11):2846-2853.
25. Wang L, Lovejoy NF, Faustman DL. Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care. 2012;35(3):465-470.